Clinical significance of KiSS-1 expression for the staging and the prediction of prognosis in patients with upper urinary tract urothelial cancer by immunohistochemistry
Not Applicable
Completed
- Conditions
- pper urinary tract urothelial cancer
- Registration Number
- JPRN-UMIN000003066
- Lead Sponsor
- Department of Urology, Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
Not provided
Exclusion Criteria
The patients who did not agree with the purpose of this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are regulated by KiSS-1 in upper urinary tract urothelial cancer progression?
How does KiSS-1 immunohistochemical expression correlate with survival outcomes in urothelial carcinoma patients?
Are KiSS-1 biomarker levels predictive of metastatic risk compared to traditional urothelial cancer markers like CK20 or p53?
What therapeutic strategies targeting metastasis could benefit from KiSS-1 expression profiling in upper urinary tract cancers?
How does KiSS-1 expression status influence treatment decisions in upper urinary tract urothelial cancer staging protocols?